Clinical trial
Memantine for Refractory OCD Patients: a Pragmatic Double Blind, Randomized, Parallel Group, Placebo Controlled, Monocentric Trial
NCT05015595 is registered in ClinicalTrials.gov with University of Roma La Sapienza as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Memantine for Refractory OCD Patients: a Pragmatic Double Blind, Randomized, Parallel Group, Placebo Controlled, Monocentric Trial
- Lead sponsor
- University of Roma La Sapienza
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- September 1, 2021
- Completion date
- December 31, 2022
- Enrollment
- 20 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.